Sarcoma expert George Demetri grades the latest statement on Nanobiotix's late-stage drug NBTXR3
The first glance at Nanobiotix’s recent round of data for its drug NBTXR3 revealed positive, but not powerful, data when used against soft tissue sarcoma. The p values were within the mark for statistical significance, but just barely. So I asked sarcoma expert George Demetri from Dana-Farber if he would take a look and give me his opinion.
Demetri took his digital highlighter and went to work on the biotech’s PR, scoring the results and offering remarks on various aspects of the company statement that I found illuminating. Rather than interpret them, I thought it would be more fun to reproduce the whole thing here, with his comments highlighted in italics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.